Drugs / HER-2/neu peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00194714 | May 2016 → Mar 2021 | HER2 positive breast carcinoma, ovarian carcinoma | University of Washington | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00194714 ↗ |
| Modality | Vaccine | “HER2 cytotoxic T-cell (CTL) peptide-based vaccine” NCT00194714 ↗ |